- GlobeNewswire•3 days agoTG Therapeutics, Inc. Announces the Launch of the Phase 1/2 Study of TGR-1202 and Carfilzomib in Patients with Relapsed or Refractory Lymphoma
Phase 1/ 2 Study to be conducted at Columbia University Medical Center. First trial to combine these two treatments to explore the synergistic effects seen on c-Myc inhibition in extensive preclinical ...
- Business Wire•3 days agoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of TG Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm
Lundin Law PC announces that it is investigating claims against TG Therapeutics, Inc. concerning possible violations of federal securities laws.
- PR Newswire•3 days agoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of TG Therapeutics, Inc. (TGTX)
NEW YORK, Oct. 19, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities TG Therapeutics, Inc. ("TG ...
TG Therapeutics, Inc. (TGTX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||6.22 x 300|
|Ask||8.02 x 100|
|Day's Range||6.00 - 6.52|
|52wk Range||5.41 - 14.87|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.09|
|Avg Vol (3m)||440,700|
|Dividend & Yield||N/A (N/A)|